Clinical Trial Update: Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating continuing everolimus beyond progression after prior everolimus plus exemestane in metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Metastatic Breast Cancer | Phase 3 | Status: TERMINATED